Skip to main content
ISPRM 2026 Main banner
Final Program


Final Congress Guide

Clinical Sciences/Health Conditions

400 Section - A randomized, double-blind, head-to-head, crossover study comparing the clinical safety and efficacy of abobotulinumtoxinA with onabotulinumtoxinA when treating adults with upper limb spasticity

Wednesday, May 20, 2026
6:00 PM - 7:30 PM PT

    Presenting Author/Autor expositor(s)

  • Alberto Esquenazi, MD

    Chief Clinical Officer
    Jefferson Moss-Magee Rehabilitation
    Elkins Park, Pennsylvania, United States

    • Co-Author/Coautor(s)

  • TW

    Theodore H H. Wein, MD

    Assistant Professor of Neurology and Neurosurgery
    McGill University Health Centre
    Montreal, Quebec, Canada

  • Monica Verduzco-Gutierrez, MD

    Professor of Rehabilitation Medicine
    Long School of Medicine at UT Health San Antonio, TX, USA
    San Antonio, Texas, United States

  • ZA

    Ziyad Ayyoub, MD

    Clinical Professor of Medicine
    David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    Los Angeles, California, United States

    • Presenting Author/Autor expositor(s)

  • SP

    Simon Page, PhD

    Global Medical Affairs Director
    Ipsen, London, United Kingdom
    London, England, United Kingdom

    • Co-Author/Coautor(s)

  • SH

    Sarah Harding, MD

    Senior Medical Director
    Ipsen, London, UK
    London, England, United Kingdom

  • PM

    Pascal Maisonobe, MS

    Biometry
    Ipsen
    Paris, Ile-de-France, France

  • MB

    Mathieu Beneteau, BA

    Biometry
    Ipsen, Paris, France
    Paris, Ile-de-France, France

  • Atul T. Patel, MD (he/him/his)

    Physiatrist
    Kansas City Bone & Joint Clinic, Overland Park, Kansas, USA
    Overland Park, Kansas, United States